Stockpolly
Search
AVTX · NASDAQ · Biotechnology

Avalo Therapeutics (AVTX)

Develops an anti-IL-1β antibody for immune-mediated inflammatory diseases.

$19.35
Pre-market−0.01 (−0.05%)
At close$19.36(+2.16%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue010000000000
Cost of revenue0000−1061110000
Gross profit010010−6−11−10000
453391413999202132
Research & development1230510891414131423
233545656778
Selling & marketing000001000000
General & administrative233544656678
Other expenses000000−6−11−10000
Operating income−4−4−33−10−13−13−15−19−19−20−21−32
−1−4−8910836−222−1−1161−5
Interest income000111111113
Interest expense200000000000
Other non-operating income0589−108−3622−2111−6−15
Income before tax−5−8−1219823−35−13−21−31−14−20−36
Income tax expense000000000000
Net income from continuing operations−5−8−1219823−35−13−21−31−14−20−36
Net income−5−8−1219823−35−13−21−31−14−20−36
EPS, basic−$26.83−$10.19−$141.14$95.21$2.83$13.89−$1.25−$1.92−$2.19−$0.74−$0.98−$0.83
EPS, diluted−$26.83−$10.19−$141.14$12.87$2.14$10.47−$1.25−$1.92−$2.19−$0.74−$0.98−$0.83
Weighted average shares, basic0111610111114192044
Weighted average shares, diluted01181110111114192044
EBITDA−4−8−1219923−35−13−21−31−14−20−36
Depreciation & amortization000000000000
EBIT−4−8−1219823−35−13−21−31−14−20−36